博安生物
No. 39 Keji Avenue
High-Tech Industrial Development Zone
Yantai
China
86 53 5437 9111
https://www.boan-bio.com
版塊: Healthcare
行業: Biotechnology
全職員工:
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Ms. Hua Jiang | Executive Chairlady & CEO | 3.29M | 無 | 1978 |
| Dr. Changlin Dou | COO, President of R&D and Executive Director | 5.06M | 無 | 1963 |
| Mr. Shenghan Wang | Chief Financial Officer | 無 | 無 | 1979 |
| Mr. Jun Lu | Senior VP and Head of Biotechnology Engineering Center & Quality Department | 無 | 無 | 1966 |
| Mr. Deyong Song | Head of Biologics Discovery Department | 無 | 無 | 1982 |
| Chunna You | Senior Vice President of R&D Center | 無 | 無 | 無 |
| Zhou Ming | Chief Medical Officer | 無 | 無 | 無 |
| Ms. Siu Kuen Lai FCIS, FCS | Company Secretary | 無 | 無 | 1976 |
描述
Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in the People's Republic of China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), advanced recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as GCTB; and LY-CovMab to treat COVID-19. It also develops BA9101 aflibercept intraocular injection to treat patients with wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, and retinopathy of prematurity; BA1104 to treat patients with melanoma, NSCLC, malignant pleural mesothelioma, RCC, classical hodgkin lymphoma, SCCHN, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal and gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma; and BA5101 to treat patients with type 2 diabetes. In addition, the company develops BA1105, a recombinant anti-Claudin 18.2 fully human IgG1 monoclonal antibody; BA1201, an anti-PD-L1/TGF-ß bifunctional fusion protein intended for the treatment of SCLC, NSCLC, cervical cancer, urothelial carcinoma, and advanced gastrointestinal tumors; BA1106, a CD25 fully human monoclonal antibody; BA1202, a bispecific antibody; and BA1301, an anti-Claudin 18.2 antibody-drug conjugate; BA2101, an IL4R long-acting molecular antibody. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
公司管治
截至 無 止，博安生物 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
